INDOUS

Indo US Bio-Tech Share Price

 

 

Start SIP in INDOUS

Start SIP

Performance

  • Low
  • ₹118
  • High
  • ₹132
  • 52 Week Low
  • ₹105
  • 52 Week High
  • ₹235
  • Open Price₹127
  • Previous Close₹125
  • Volume7,295
  • 50 DMA₹123.21
  • 100 DMA₹130.81
  • 200 DMA₹148.29

Investment Returns

  • Over 1 Month -1.76%
  • Over 3 Month -10.68%
  • Over 6 Month -31.48%
  • Over 1 Year -46.6%

Smart Investing Starts Here Start SIP with Indo US Bio-Tech for Steady Growth!

Invest Now

Indo US Bio-Tech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 16.2
  • PEG Ratio
  • 1.2
  • Market Cap Cr
  • 241
  • P/B Ratio
  • 2.8
  • Average True Range
  • 8.39
  • EPS
  • 7.4
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.02
  • RSI
  • 49.17
  • MFI
  • 29.85

Indo US Bio-Tech Financials

Indo US Bio-Tech Technicals

EMA & SMA

Current Price
₹120.05
-6.05 (-4.8%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹120.57
  • 50 Day
  • ₹123.21
  • 100 Day
  • ₹130.81
  • 200 Day
  • ₹148.29

Resistance and Support

124.47 Pivot Speed
  • R3 142.13
  • R2 137.72
  • R1 128.88
  • S1 115.63
  • S2 111.22
  • S3 102.38

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Indo Us Bio-Tech has an operating revenue of Rs. 117.80 Cr. on a trailing 12-month basis. An annual revenue growth of 42% is outstanding, Pre-tax margin of 16% is great, ROE of 20% is exceptional. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 44 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 104 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Indo US Bio-Tech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-21 Quarterly Results
2025-11-14 Quarterly Results
2025-10-14 Others Inter-alia, to consider 1. Re-appointment of M/s. Gautam N Associates as a Statutory Auditors of the Company. 2. Approve Notice of Postal Ballot. 3. Other business matters. per share(2.5%)Interim Dividend
2025-08-12 Quarterly Results
2025-05-26 Audited Results
Date Purpose Remarks
2024-12-03 INTERIM Rs.0.25 per share(2.5%)Interim Dividend
2021-10-29 INTERIM Rs.0.25 per share(2.5%)Interim Dividend
View Indo US Bio-Tech Dividend History Arrow
Date Purpose Remarks
2023-08-29 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.
2021-11-30 Bonus Rs.0.00 issue in the ratio of 1:5 of Rs. 10/-.

Indo US Bio-Tech F&O

Indo US Bio-Tech Shareholding Pattern

70.17%
0%
23.69%
6.14%

About Indo US Bio-Tech

  • NSE Symbol
  • INDOUS
  • BSE Symbol
  • 541304
  • Managing Director
  • Mr. Jagdish Ajudia
  • ISIN
  • INE250Z01010

Similar Stocks to Indo US Bio-Tech

Indo US Bio-Tech FAQs

Indo US Bio-Tech share price is ₹120 As on 02 February, 2026 | 02:21

The Market Cap of Indo US Bio-Tech is ₹240.7 Cr As on 02 February, 2026 | 02:21

The P/E ratio of Indo US Bio-Tech is 16.2 As on 02 February, 2026 | 02:21

The PB ratio of Indo US Bio-Tech is 2.8 As on 02 February, 2026 | 02:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23